Plasma concentrations/clinical effects of perampanel 4 mg/day monotherapy for focal-onset seizures (FOS): post hoc analysis by body mass index (BMI)

被引：0
|
作者：
Leppik, Ilo E. [1 ]
Yamamoto, Takamichi [2 ]
Ngo, Leock Y. [3 ]
Yasuda, Sanae [3 ]
Patten, Anna [4 ]
Hiramatsu, Hidetaka [5 ]
Watanabe, Kazuaki [5 ]
Shiba, Sari [5 ]
Malhotra, Manoj [3 ]
机构：
[1] Univ Minnesota, Minneapolis, MN USA
[2] Seirei Hamamatsu Gen Hosp, Hamamatsu, Shizuoka, Japan
[3] Eisai Inc, Woodcliff Lake, NJ USA
[4] Eisai Europe Ltd, Hatfield, Herts, England
[5] Eisai & Co Ltd, Tokyo, Japan
来源：
EPILEPSIA | 2021年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
228
引用
收藏
页码：147 / 148
页数：2
相关论文
共 18 条
  • [1] Adjunctive perampanel 4 mg/day for focal-onset seizures (FOS): Time to seizure onset in pivotal phase III studies
    Salah, Alejandro
    Patten, Anna
    Malhotra, Manoj
    EPILEPSIA, 2021, 62 : 42 - 43
  • [2] Clinical factors associated with seizure freedom in patients with focal-onset seizures (FOS) receiving perampanel 4 mg/day in FREEDOM study 342
    Yamamoto, Takamichi
    Patten, Anna
    Kim, Ji Hyun
    Lim, Sung Chul
    Ninomiya, Hirotomo
    Kubota, Yuichi
    Malhotra, Manoj
    EPILEPSIA, 2021, 62 : 45 - 46
  • [3] Perampanel Monotherapy Beyond Initial Titration to Achieve Seizure Freedom in Patients with Focal-Onset Seizures: Post Hoc Analysis of Study 342
    Husni, Ryan Edbert
    Ngo, Leock Y.
    Patten, Anna
    Hiramatsu, Hidetaka
    Watanabe, Kazuaki
    Senokuchi, Hirofumi
    Yamamoto, Takamichi
    EPILEPSIA, 2021, 62 : 54 - 55
  • [4] Sustained Seizure Freedom with Perampanel 4 mg/day Monotherapy in Patients with Newly Diagnosed/Currently Untreated Focal-Onset Seizures: Study 342
    Kubota, Yuichi
    Kim, Ji Hyun
    Lim, Sung Chul
    Ninomiya, Hirotomo
    Yamamoto, Takamichi
    Patten, Anna
    Ngo, Leock Y.
    Malhotra, Manoj
    EPILEPSIA, 2021, 62 : 45 - 45
  • [5] Efficacy and Safety of Perampanel in Patients with Focal-Onset Seizures (FOS): Post Hoc Analysis of FAME by Dose and First-Line Antiepileptic Drug
    Kim, Min Young
    Malhotra, Manoj
    Dash, Amitabh
    Lee, JiWoong
    EPILEPSIA, 2021, 62 : 40 - 41
  • [6] Safety of adjunctive perampanel by titration/maintenance periods and dose in patients with focal-onset seizures: Post hoc analysis of the FAME study
    Kim, Dong Wook
    Kim, Ji Hyun
    Dash, Amitabh
    Lee, JiWoong
    Malhotra, Manoj
    EPILEPSIA, 2021, 62 : 43 - 44
  • [7] Effect of low dose (4 mg/day) perampanel on efficacy and safety outcomes from a mirroring clinical practice study of adjunctive perampanel in adults and adolescents with focal-onset seizures
    Giallonardo, A. T.
    Aguglia, U.
    Goldman, S.
    Chiacchiaretta, M.
    Gentile, A.
    Patten, A.
    EPILEPSIA, 2022, 63 : 128 - 129
  • [8] A multivariable prediction model of a major treatment response for focal-onset seizures: A post-hoc analysis of Phase III trials of perampanel
    Krauss, Gregory L.
    Ben-Menachem, Elinor
    Wechsler, Robert T.
    Patten, Anna
    Williams, Betsy
    Laurenza, Antonio
    Malhotra, Manoj
    EPILEPSY RESEARCH, 2021, 174
  • [9] Efficacy and safety of adjunctive perampanel 4 mg/day in patients aged 4-<12 years with focal-onset seizures or generalised tonic-clonic seizures
    Moretz, Katherine
    Malhotra, Manoj
    Patten, Anna
    Ngo, Leock Y.
    EPILEPSIA, 2021, 62 : 269 - 269
  • [10] Efficacy/Safety of Low-/High-Dose Perampanel as First Adjunctive Therapy in Patients With Focal-Onset Seizures: Post Hoc Analysis of the FAME Study
    Seo, Dae Won
    Lee, JiWoong
    Dash, Amitabh
    Lee, Sang Kun
    Lee, Sang-Ahm
    Malhotra, Manoj
    EPILEPSIA, 2021, 62 : 51 - 51
12